Marked Improvement of Diabetic Diarrhea With the Somatostatin Analogue Octreotide

Nakabayashi, Hajime; Fujii, Sumie; Miwa, Umeo; Seta, Takashi; Takeda, Ryoyu

doi:10.1001/archinte.1994.00420160103014

Cited by 13 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[92][93][94][95][96] SST receptors are localized both in the periphery (including the GI tract) and the CNS, and SST receptor-mediated signalling is involved in pain modulation, as well as vascular, neuroendocrine, neuronal and autonomic responses. 97 The localization of SST2 receptors on spinal afferents, superficial dorsal horn neurons and within the locus coeruleus complex is similar to those of mu opioid receptors and makes this class of receptors an attractive target for the treatment of visceral hypersensitivity.…”

Section: Somatostatin Receptor Agonistsmentioning

confidence: 99%

Review article: modulation of the brain–gut axis as a therapeutic approach in gastrointestinal disease

Mayer¹,

Tillisch²,

Bradesi³

2006

Aliment Pharmacol Ther

121

View full text Add to dashboard Cite

SummaryBackgroundThe importance of bi‐directional brain‐gut interactions in gastrointestinal illness is increasingly being recognized, most prominently in the area of functional gastrointestinal disorders. Numerous current and emerging therapies aimed at normalizing brain–gut interactions are a focus of interest, particularly for irritable bowel syndrome and functional dyspepsia.MethodsA literature search was completed for preclinical and clinical studies related to central modulation of gastrointestinal functions and published in English between 1980 and 2006.ResultsExisting data, while sparse, support the use of different classes of antidepressant drugs, including tricyclics, and selective and non‐selective serotonin reuptake inhibitors in irritable bowel syndrome. Serotonin receptor agonists and antagonists with peripheral and possibly central effects are effective in treating specific subtypes of irritable bowel syndrome. Based largely on theoretical and preclinical evidence, several novel compounds that selectively target receptors at multiple levels within the brain–gut axis such as neurokinin, somatostatin and corticotropin‐releasing factor receptor antagonists are promising.ConclusionsThis review discusses the rationale for modulation of the brain–gut axis in the treatment of functional gastrointestinal disorders and highlights the most promising current and future therapeutic strategies.

show abstract

Section: Somatostatin Receptor Agonistsmentioning

confidence: 99%

Review article: modulation of the brain–gut axis as a therapeutic approach in gastrointestinal disease

Mayer¹,

Tillisch²,

Bradesi³

2006

Aliment Pharmacol Ther

121

View full text Add to dashboard Cite

show abstract

“…Our cases demonstrate effectiveness of octreotide in severe diabetic diarrhoea. Its efficacy in this condition is well‐recognized, being cited in recent textbooks of diabetes 6 and case reports 5,7 . The cost per patient per year is approximately $A10,000−20 000 in Australia and New Zealand, although this must be balanced against savings made by reduced hospital admissions and return to work.…”

mentioning

confidence: 99%

Octreotide treatment of severe diabetic diarrhoea

Meyer

O’Neal

Connell

et al. 2003

Internal Medicine Journal

View full text Add to dashboard Cite

“…Octreotide may be employed in the treatment of AIDS-associated diarrhea if treatment of severe refractory diarrhea in patients with diabetes mellitus [30][31][32].…”

Section: Conclusion Miscellaneous Indicationsmentioning

confidence: 99%

Octreotide in the Treatment of Refractory Diarrhea

Fried

1999

Digestion

View full text Add to dashboard Cite

Refractory chronic diarrhea that does not respond to specific antimicrobial therapy or standard unspecific medication may present a challening and serious clinical problem. Octreotide is a candidate drug for the treatment of these patients as it inhibits gastrointestinal motility, pancreatic secretion and inhibits intestinal absorption. Only few mostly uncontrolled studies in small patient groups were published evaluating the efficacy of octreotide in the treatment of patients with chemotherapy-induced diarrhea, short-bowel syndrome, AIDS-associated diarrhea and other conditions with chronic diarrhea not responding to standard treatment. Most of these studies are not conclusive as they yielded either negative or controversial results. Octreotide may be tried in the treatment of refractory diarrhea, in particular AIDS-associated diarrhea if patients do not respond to conventional treatment strategies. Well-designed controlled trials in large patient groups are needed in order to define the place of octreotide in the treatment of patients with refractory diarrhea.

show abstract

Marked Improvement of Diabetic Diarrhea With the Somatostatin Analogue Octreotide

Cited by 13 publications

References 19 publications

Review article: modulation of the brain–gut axis as a therapeutic approach in gastrointestinal disease

Review article: modulation of the brain–gut axis as a therapeutic approach in gastrointestinal disease

Octreotide treatment of severe diabetic diarrhoea

Octreotide in the Treatment of Refractory Diarrhea

Contact Info

Product

Resources

About